Cardium Therapeutics, Inc. (CXM) Enters Distribution Agreement Targeting Governmental Medical Facilities

MissionIR would like to highlight Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. The company's lead commercial product Excellagen topical gel for wound care management, has FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands develops, markets, and sells dietary supplements through established regional and national retailers.

In the company’s news,

Cardium Therapeutics announced that it has signed a distribution agreement with AvKARE encompassing government medical facilities throughout the United States. The new commercialization arrangement with AvKARE effectively replaces an earlier arrangement with Academy Medical.

Cardium chose to transfer the Excellagen distribution responsibilities to AvKARE, a licensed manufacturer/wholesaler of pharmaceuticals, disposable medical supplies, and capital medical equipment. The officers and management team at AvKARE have more than 80 years’ experience in the pharmaceutical and medical supply industry.

As part of the agreement, AvKARE provides five direct wound care experts and allows Cardium’s 25 distributor representatives access to all government accounts. The company serves the Department of Defense, Veterans Hospitals, NASA, TriCare, Dept. of Agriculture, Indian Health Services, USDA, U.S. Army, Air Force, Navy, and USMC, as well as Group Purchasing Organizations that include Amerinet, Innovatix, Health Trust Purchasing Group, IPC, Broadlane/MedAssets and Premier.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.